WO2005023291A3 - Use of glp1-agonists in the treatment of patients with type i diabetes - Google Patents

Use of glp1-agonists in the treatment of patients with type i diabetes Download PDF

Info

Publication number
WO2005023291A3
WO2005023291A3 PCT/DK2004/000599 DK2004000599W WO2005023291A3 WO 2005023291 A3 WO2005023291 A3 WO 2005023291A3 DK 2004000599 W DK2004000599 W DK 2004000599W WO 2005023291 A3 WO2005023291 A3 WO 2005023291A3
Authority
WO
WIPO (PCT)
Prior art keywords
diabetes
type
patients
treatment
glp
Prior art date
Application number
PCT/DK2004/000599
Other languages
French (fr)
Other versions
WO2005023291A2 (en
Inventor
Lars Hansen
Henrik Bindesboel Mortensen
Original Assignee
Novo Nordisk As
Koebenhavns Amt
Lars Hansen
Henrik Bindesboel Mortensen
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk As, Koebenhavns Amt, Lars Hansen, Henrik Bindesboel Mortensen filed Critical Novo Nordisk As
Publication of WO2005023291A2 publication Critical patent/WO2005023291A2/en
Publication of WO2005023291A3 publication Critical patent/WO2005023291A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/26—Glucagons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/72—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving blood pigments, e.g. haemoglobin, bilirubin or other porphyrins; involving occult blood
    • G01N33/721—Haemoglobin
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/74—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving hormones or other non-cytokine intercellular protein regulatory factors such as growth factors, including receptors to hormones and growth factors

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Hematology (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • General Physics & Mathematics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Food Science & Technology (AREA)
  • Epidemiology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Obesity (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

The present invention relates to the use of GLP-1 agonists in the treatment of patients with type I diabetes, where the patient is newly diagnosed with type 1 diabetes when treatment with the GLP-1 agonist is initiated. The present invention also relates to the use of GLP-1 agonists to prolong the remission period in such patients. The present invention further re-lates to a diagnostic test which utilizes measurement of endogenous GLP-1 levels to predict loss of beta cell function in patients with type I diabetes. The present invention further relates to methods for determining whether a patient with type 1 diabetes is in need of treatment with a GLP-1 agonist and/or is in remission.
PCT/DK2004/000599 2003-09-11 2004-09-10 Use of glp1-agonists in the treatment of patients with type i diabetes WO2005023291A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
DKPA200301321 2003-09-11
DKPA200301321 2003-09-11
US50550003P 2003-09-24 2003-09-24
US60/505,500 2003-09-24

Publications (2)

Publication Number Publication Date
WO2005023291A2 WO2005023291A2 (en) 2005-03-17
WO2005023291A3 true WO2005023291A3 (en) 2005-04-28

Family

ID=34276709

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/DK2004/000599 WO2005023291A2 (en) 2003-09-11 2004-09-10 Use of glp1-agonists in the treatment of patients with type i diabetes

Country Status (1)

Country Link
WO (1) WO2005023291A2 (en)

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2658673A1 (en) 2005-07-27 2008-02-01 Gerald J. Prud'homme Composition and method for prevention and treatment of type i and type ii diabetes
US20090074734A1 (en) * 2006-05-02 2009-03-19 Actogenix N.V. Microbial intestinal delivery of obesity related peptides
DK2349324T3 (en) 2008-10-17 2017-12-11 Sanofi Aventis Deutschland COMBINATION OF AN INSULIN AND A GLP-1 AGONIST
JP5973918B2 (en) 2009-11-13 2016-08-23 サノフィ−アベンティス・ドイチュラント・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング Pharmaceutical composition comprising a GLP-1 agonist and methionine
KR101836070B1 (en) 2009-11-13 2018-03-09 사노피-아벤티스 도이칠란트 게엠베하 Pharmaceutical composition comprising a glp-1 agonist, an insulin, and methionine
PT2611458T (en) 2010-08-30 2016-12-16 Sanofi Aventis Deutschland Use of ave0010 for the manufacture of a medicament for the treatment of diabetes mellitus type 2
EP2668951B9 (en) 2011-01-25 2017-03-15 Viviabiotech, S.L. 1,2,4-oxadiazole derivatives as drugs modulating the glp-1 peptide receptor
US9821032B2 (en) 2011-05-13 2017-11-21 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for improving glycemic control as add-on therapy to basal insulin
PL3139948T3 (en) 2014-05-07 2020-08-10 Novo Nordisk A/S Treatment of diabetes type 1 using glp-1 and anti-il-21
CN107206058A (en) 2014-12-12 2017-09-26 赛诺菲-安万特德国有限公司 Insulin glargine/lixisenatide fixed ratio preparaton
TWI748945B (en) 2015-03-13 2021-12-11 德商賽諾菲阿凡提斯德意志有限公司 Treatment type 2 diabetes mellitus patients
TW201705975A (en) 2015-03-18 2017-02-16 賽諾菲阿凡提斯德意志有限公司 Treatment of type 2 diabetes mellitus patients
WO2019200594A1 (en) 2018-04-19 2019-10-24 杭州先为达生物科技有限公司 Acylated glp-1 derivative
MX2021013413A (en) * 2019-05-02 2022-02-11 Closed Loop Medicine Ltd Methods and systems for providing personalised medicine to a patient.

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201187A1 (en) * 1985-03-29 1986-11-12 Novo Nordisk A/S Determination of glycated (glycosylated) hemoglobin in blood
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995031214A1 (en) * 1994-05-12 1995-11-23 London Health Association Treatment of diabetes
WO1998008871A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0201187A1 (en) * 1985-03-29 1986-11-12 Novo Nordisk A/S Determination of glycated (glycosylated) hemoglobin in blood
US5424286A (en) * 1993-05-24 1995-06-13 Eng; John Exendin-3 and exendin-4 polypeptides, and pharmaceutical compositions comprising same
WO1995031214A1 (en) * 1994-05-12 1995-11-23 London Health Association Treatment of diabetes
WO1998008871A1 (en) * 1996-08-30 1998-03-05 Novo Nordisk A/S Glp-1 derivatives
WO2000042026A1 (en) * 1999-01-15 2000-07-20 Novo Nordisk A/S Non-peptide glp-1 agonists
WO2003002136A2 (en) * 2001-06-28 2003-01-09 Novo Nordisk A/S Stable formulation of modified glp-1
WO2004050115A2 (en) * 2002-12-03 2004-06-17 Novo Nordisk A/S Combination treatment using exendin-4 and thiazolidinediones

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
DANNE T ET AL: "Persistent differences among centers over 3 years in glycemic control and hypoglycemia in a study of 3,805 children and adolescents with type 1 diabetes from the Hvidore Study Group.", DIABETES CARE. AUG 2001, vol. 24, no. 8, August 2001 (2001-08-01), pages 1342 - 1347, XP002319817, ISSN: 0149-5992 *
HOEY H ET AL: "Good metabolic control is associated with better quality of life in 2,101 adolescents with type 1 diabetes.", DIABETES CARE. NOV 2001, vol. 24, no. 11, November 2001 (2001-11-01), pages 1923 - 1928, XP002319818, ISSN: 0149-5992 *
NORDLY S ET AL: "Quality of diabetes management in children and adolescents in Denmark.", DIABETIC MEDICINE : A JOURNAL OF THE BRITISH DIABETIC ASSOCIATION. JUL 2003, vol. 20, no. 7, July 2003 (2003-07-01), pages 568 - 574, XP002319819, ISSN: 0742-3071 *
OLSEN BIRTHE SUSSANE ET AL: "A 6-year nationwide cohort study of glycaemic control in young people with Type 1 diabetes: Risk markers for the development of retinopathy, nephropathy, and neuropathy", JOURNAL OF DIABETES AND ITS COMPLICATIONS, vol. 14, no. 6, November 2000 (2000-11-01), pages 295 - 300, XP002319816, ISSN: 1056-8727 *
VILSBOELL T ET AL: "EVALUATION OF BETA-CELL SECRETORY CAPACITY USING GLUCAGON-LIKE PEPTIDE 1", DIABETES CARE, AMERICAN DIABETES ASSOCIATION, ALEXANDRIA, VA, US, vol. 23, no. 6, June 2000 (2000-06-01), pages 807 - 812, XP000984497, ISSN: 0149-5992 *

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9408893B2 (en) 2011-08-29 2016-08-09 Sanofi-Aventis Deutschland Gmbh Pharmaceutical combination for use in glycemic control in diabetes type 2 patients
US9364519B2 (en) 2011-09-01 2016-06-14 Sanofi-Aventis Deutschland Gmbh Pharmaceutical composition for use in the treatment of a neurodegenerative disease

Also Published As

Publication number Publication date
WO2005023291A2 (en) 2005-03-17

Similar Documents

Publication Publication Date Title
WO2005023291A3 (en) Use of glp1-agonists in the treatment of patients with type i diabetes
Blüher et al. Relation between glycaemic control, hyperinsulinaemia and plasma concentrations of soluble adhesion molecules in patients with impaired glucose tolerance or Type II diabetes
Brydon et al. Stress-induced increases in interleukin-6 and fibrinogen predict ambulatory blood pressure at 3-year follow-up
Kuwa et al. Relationships of glucose concentrations in capillary whole blood, venous whole blood and venous plasma
EP3712279B1 (en) Methods for diagnosing and evaluating non-alcoholic steatohepatitis
Berends et al. Biochemical and biophysical assessment of MTX‐induced liver fibrosis in psoriasis patients: Fibrotest predicts the presence and Fibroscan® predicts the absence of significant liver fibrosis
EP2113774A3 (en) PIGF and Flt-1 as prognostic parameters for cardiovascular illnesses
CA2684144C (en) Measurement and uses of oxidative status
TW200600060A (en) Apparatus for the manufacture of medical devices
WO2008005814A3 (en) Method and apparatus for diagnosing pre-eclampsia
Hannon et al. Use of markers of dyslipidemia to identify overweight youth with insulin resistance
Michel et al. Urinary angiotensinogen excretion is associated with blood pressure independent of the circulating renin–angiotensin system in a group of African ancestry
WO2007015113A3 (en) New protein isoforms of the pif-family and uses thereof
Veilleux et al. Quality of life in neurooncology—age matters
Yılmaz Agladioglu et al. Urinary C-peptide/creatinine ratio can distinguish maturity-onset diabetes of the young from type 1 diabetes in children and adolescents: a single-center experience
WO2006116688A3 (en) Mif agonists and antagonists and therapeutic uses thereof
EP2044212A4 (en) Methods for identifying patients with increased risk of an adverse cardiovascular event
ATE479707T1 (en) DIAGNOSIS AND RECORDING OF SYSTEMIC LUPUS ERYTHEMATOSUS AND SCLERODERM
WO2005079410A3 (en) Biological profiles and methods of use
NZ540750A (en) Sets of oligonucleotide probes for diagnosis
Caputo et al. What is the real contribution of fasting plasma glucose and postprandial glucose in predicting HbA (1c) and overall blood glucose control?
Graci et al. The intravenous insulin tolerance test is an accurate method for screening a general population for insulin resistance and related abnormalities
Raju et al. Observation of estimated GFR in the assessment of chronic kidney disease: application and practice
Lippi et al. Circulating cardiac troponin T is not influenced by postural changes during venous blood collection
Zachrissons et al. Determinants of blood glucose variability in adolescents with insulin‐dependent diabetes mellitus

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
122 Ep: pct application non-entry in european phase